09/12/2025 00:11
|
Medical, Health & Aged Care
Multiple long-term follow-up studies confirm BRUKINSA’s superior efficacy and favorable tolerability versus ibrutinib in relapsed or refractory CLL
Additional ASH data from investigational BTK...